Diltiazem 12-Hour Sustained-Release Capsules and Olysio
Determining the interaction of Diltiazem 12-Hour Sustained-Release Capsules and Olysio and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Simeprevir may increase the blood levels of dilTIAZem. You may be more likely to experience serious side effects such as irregular heart rhythm, fluid retention, swelling, heart failure, and excessively low blood pressure. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek medical attention if you develop dizziness or fainting; sudden, unexplained weight gain; swelling of the hands, ankles, or feet; chest pain; or difficulty breathing during treatment with these medications. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with simeprevir may increase the plasma concentrations and pharmacologic effects of calcium channel blockers, especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves simeprevir inhibition of CYP450 3A4-mediated metabolism and P-glycoprotein-mediated efflux in the intestine. The interaction is not expected to occur with intravenously administered agents, since simeprevir does not affect hepatic CYP450 3A4 activity.
MANAGEMENT: Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with simeprevir. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.
- "Product Information. Olysio (simeprevir)." Janssen Pharmaceuticals, Titusville, NJ.
Generic Name: diltiazem
Brand name: Cardizem, Cartia XT, Dilacor XR, Dilt-CD, Diltia XT, Dilt-XR, Diltzac, Matzim LA, Taztia XT, Tiazac, Cardizem CD, Tiazac, Cardizem LA, Tiazac Extended Release Capsules
Synonyms: Diltiazem
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Diltiazem 12-Hour Sustained-Release Capsules-Omacetaxine
- Diltiazem 12-Hour Sustained-Release Capsules-Omacetaxine Mepesuccinate
- Diltiazem 12-Hour Sustained-Release Capsules-Omacetaxine Subcutaneous
- Diltiazem 12-Hour Sustained-Release Capsules-Omacor
- Diltiazem 12-Hour Sustained-Release Capsules-Omadacycline
- Diltiazem 12-Hour Sustained-Release Capsules-Omadacycline Injection
- Olysio-Diltiazem CD
- Olysio-Diltiazem Extended Release Tablets
- Olysio-Diltiazem Hydrochloride
- Olysio-Diltiazem Injection
- Olysio-Diltiazem Intravenous
- Olysio-Diltiazem Long-Acting Capsules